Mir21 (microRNA 21) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Mir21 (microRNA 21) Rattus norvegicus
Symbol: Mir21
Name: microRNA 21
RGD ID: 2325598
Description: Predicted to enable mRNA 3'-UTR binding activity and mRNA base-pairing translational repressor activity. Involved in several processes, including cellular response to mechanical stimulus; cellular response to oxidative stress; and negative regulation of programmed cell death. Located in extracellular vesicle. Used to study glioblastoma; status epilepticus; and thyroid gland cancer. Biomarker of several diseases, including cerebral infarction; diabetic retinopathy; pulmonary hypertension; sciatic neuropathy; and status epilepticus. Orthologous to human MIR21 (microRNA 21); INTERACTS WITH (R)-lipoic acid; 17beta-estradiol; 2,5-hexanedione.
Type: ncrna (Ensembl: miRNA)
Previously known as: microRNA mir-21; rno-mir-21
RGD Orthologs
Alliance Genes
More Info more info ...
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21071,405,257 - 71,405,348 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1071,405,257 - 71,405,348 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1076,026,707 - 76,026,798 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01075,531,582 - 75,531,673 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01070,996,132 - 70,996,223 (-)NCBIRnor_WKY
Rnor_6.01073,902,210 - 73,902,301 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1073,902,210 - 73,902,301 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01076,197,081 - 76,197,172 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1070,326,375 - 70,326,466 (-)NCBICelera
Cytogenetic Map10q26NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
Acute Lung Injury  (IEP)
acute myocardial infarction  (ISO)
allergic contact dermatitis  (IEP)
Angina Pectoris  (ISO)
atherosclerosis  (ISO)
Atrial Remodeling  (IEP)
autoimmune uveitis  (ISO)
brain glioma  (ISO)
breast cancer  (IEP,ISO)
Burkitt lymphoma  (ISO)
Cardio-Renal Syndrome  (IMP)
Cardiomegaly  (ISO)
cerebral infarction  (IEP)
cervical cancer  (ISO)
cervical squamous cell carcinoma  (ISO)
cervicitis  (ISO)
cervix uteri carcinoma in situ  (ISO)
Chemical and Drug Induced Liver Injury  (ISO)
chlamydia  (ISO)
cholangiocarcinoma  (ISO)
Cholangiofibrosis  (ISO)
Chronic Hepatitis  (ISO)
chronic lymphocytic leukemia  (ISO)
colon cancer  (ISO)
colorectal cancer  (ISO)
congestive heart failure  (IEP,ISO)
coronary artery disease  (ISO)
Crohn's disease  (ISO)
cryptosporidiosis  (ISO)
dengue disease  (ISO)
Diabetic Nephropathies  (IEP)
diabetic retinopathy  (IEP)
Disease Progression  (ISO)
endometrial cancer  (ISO)
endometriosis  (ISO)
esophageal cancer  (ISO)
Esophageal Neoplasms  (ISO)
esophagus adenocarcinoma  (ISO)
Experimental Colitis  (ISO)
Fibrosis  (ISO)
Fusobacterium Infections  (ISO)
glioblastoma  (IMP)
Haemophilus Infections  (ISO)
heart disease  (ISO)
hepatitis C  (ISO)
hepatoblastoma  (ISO)
hepatocellular carcinoma  (ISO)
Hyperoxic Lung Injury  (IDA,IMP)
hypertensive heart disease  (ISO)
Inflammation  (ISO)
influenza  (ISO)
intestinal obstruction  (ISO)
Intestinal Reperfusion Injury  (IEP)
intrahepatic cholangiocarcinoma  (ISO)
irritable bowel syndrome  (ISO)
Joubert syndrome  (ISO)
kidney disease  (ISO)
laryngeal squamous cell carcinoma  (ISO)
listeriosis  (ISO)
liver cirrhosis  (IEP,ISO)
Liver Reperfusion Injury  (IEP)
lung adenocarcinoma  (ISO)
lung adenoma  (ISO)
lung cancer  (ISO)
lung carcinoma  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
Microsatellite Instability  (ISO)
Myocardial Reperfusion Injury  (IEP,ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
Neoplastic Cell Transformation  (ISO)
non-alcoholic steatohepatitis  (ISO)
obesity  (ISO)
papillomavirus infectious disease  (ISO)
Parkinson's disease  (IEP)
Peritoneal Fibrosis  (IEP)
peritonitis  (ISO)
primary biliary cholangitis  (ISO)
Prostatic Neoplasms  (ISO)
pulmonary fibrosis  (IEP)
pulmonary hypertension  (IEP)
respiratory syncytial virus infectious disease  (ISO)
sciatic neuropathy  (IEP)
skin melanoma  (ISO)
skin papilloma  (ISO)
Spinal Cord Injuries  (IMP)
status epilepticus  (IEP,IMP)
stomach cancer  (ISO)
thyroid gland anaplastic carcinoma  (ISO)
thyroid gland cancer  (IMP)
toxic shock syndrome  (ISO)
Varicose Ulcer  (ISO)
Viral Myocarditis  (ISO)
visceral leishmaniasis  (ISO)
Weight Gain  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-Arctigenin  (ISO)
(R)-lipoic acid  (EXP)
1,2-dichloroethane  (ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
2,3-bis(4-hydroxyphenyl)propionitrile  (ISO)
2,5-hexanedione  (EXP)
2-acetamidofluorene  (EXP)
2-hydroxypropanoic acid  (ISO)
3,7-dihydropurine-6-thione  (EXP)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (ISO)
acetic acid  (EXP)
actinomycin D  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP)
all-trans-retinoic acid  (ISO)
Allylamine  (EXP)
aluminium atom  (ISO)
aluminium(0)  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (ISO)
antigen  (ISO)
antirheumatic drug  (ISO)
aristolochic acid A  (EXP)
arsane  (ISO)
arsenic atom  (ISO)
arsenic trichloride  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (EXP,ISO)
baicalein  (ISO)
Bandrowski's base  (ISO)
benomyl  (EXP)
berberine  (ISO)
bicalutamide  (ISO)
biphenyl-4-amine  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bisphenol A  (ISO)
bleomycin A2  (EXP)
bortezomib  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
cannabidiol  (ISO)
carbamazepine  (ISO)
carbon atom  (ISO)
carbon monoxide  (ISO)
chromium(6+)  (ISO)
cisplatin  (EXP,ISO)
cobalt atom  (ISO)
copper atom  (EXP)
copper(0)  (EXP)
coumestrol  (ISO)
curcumin  (ISO)
cycloheximide  (ISO)
cyclosporin A  (EXP)
daunorubicin  (ISO)
dehydroepiandrosterone  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (EXP,ISO)
dioxygen  (EXP)
dorsomorphin  (ISO)
doxorubicin  (ISO)
elemental carbon  (ISO)
Enterolactone  (ISO)
fenhexamid  (ISO)
ferulic acid  (EXP)
fludioxonil  (ISO)
formaldehyde  (ISO)
fulvestrant  (ISO)
gallic acid  (EXP)
geldanamycin  (ISO)
gentamycin  (EXP)
graphene oxide  (ISO)
halothane  (ISO)
hydrogen peroxide  (ISO)
icariin  (ISO)
isoprenaline  (EXP)
lamotrigine  (ISO)
lipoic acid  (EXP)
LY294002  (ISO)
mechlorethamine  (EXP)
medroxyprogesterone acetate  (ISO)
mercaptopurine  (EXP)
methapyrilene  (EXP)
methyl beta-cyclodextrin  (ISO)
methylmercury chloride  (ISO)
morphine  (ISO)
myo-inositol hexakisphosphate  (EXP)
N-acetyl-L-cysteine  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (ISO)
nickel atom  (ISO)
nickel dichloride  (ISO)
nickel sulfate  (ISO)
nitrofen  (EXP)
notoginsenoside R1  (ISO)
ochratoxin A  (ISO)
ozone  (ISO)
paracetamol  (EXP,ISO)
paraquat  (ISO)
perfluorooctane-1-sulfonic acid  (EXP)
phenylephrine  (EXP)
phenylmercury acetate  (ISO)
piperacillin  (ISO)
potassium bromate  (ISO)
progesterone  (ISO)
purine-6-thiol  (EXP)
quercetin  (EXP,ISO)
quercetin 3-O-beta-D-galactopyranoside  (ISO)
rac-lactic acid  (ISO)
resveratrol  (EXP,ISO)
rifampicin  (ISO)
SB 431542  (ISO)
sodium arsenate  (ISO)
sodium arsenite  (ISO)
sodium fluoride  (ISO)
solasodine  (ISO)
sporidesmin A  (ISO)
stattic  (ISO)
sulfamethoxazole  (ISO)
sulfur dioxide  (ISO)
tacrolimus hydrate  (ISO)
Tanshinone I  (ISO)
tetrachloromethane  (EXP)
thioacetamide  (EXP)
titanium dioxide  (ISO)
trichostatin A  (ISO)
Tungsten carbide  (ISO)
tyrphostin AG 1478  (ISO)
ursodeoxycholic acid  (EXP,ISO)
valproic acid  (ISO)
wortmannin  (ISO)
zinc atom  (EXP)
zinc(0)  (EXP)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
activation of protein kinase B activity  (ISO)
BMP signaling pathway  (ISO)
cellular response to angiotensin  (IEP)
cellular response to decreased oxygen levels  (ISO)
cellular response to dexamethasone stimulus  (ISO)
cellular response to gamma radiation  (ISO)
cellular response to glucose stimulus  (IEP)
cellular response to granulocyte macrophage colony-stimulating factor stimulus  (ISO)
cellular response to hydrogen peroxide  (IEP)
cellular response to interleukin-6  (ISO)
cellular response to leukemia inhibitory factor  (ISO)
cellular response to lipopolysaccharide  (IEP,ISO)
cellular response to mechanical stimulus  (IEP)
cellular response to transforming growth factor beta stimulus  (ISO)
endothelial tube morphogenesis  (ISO)
epithelial to mesenchymal transition involved in cardiac fibroblast development  (ISO)
female pregnancy  (ISO)
inflammatory response to antigenic stimulus  (ISO)
miRNA-mediated gene silencing  (ISO)
miRNA-mediated gene silencing by inhibition of translation  (ISO)
negative regulation of angiogenesis  (IMP)
negative regulation of aortic smooth muscle cell differentiation  (ISO)
negative regulation of apoptotic process  (IMP,ISO)
negative regulation of cardiac muscle cell apoptotic process  (IMP)
negative regulation of cartilage development  (ISO)
negative regulation of cell migration  (ISO)
negative regulation of cell population proliferation  (ISO)
negative regulation of chondrocyte proliferation  (ISO)
negative regulation of cytokine-mediated signaling pathway  (ISO)
negative regulation of endothelial cell migration  (ISO)
negative regulation of endothelial cell proliferation  (ISO)
negative regulation of ERK1 and ERK2 cascade  (ISO)
negative regulation of fibroblast apoptotic process  (IDA)
negative regulation of gene expression  (ISO)
negative regulation of GTPase activity  (ISO)
negative regulation of hepatocyte apoptotic process  (IMP)
negative regulation of hydrogen peroxide-mediated programmed cell death  (IMP)
negative regulation of hydrogen sulfide biosynthetic process  (ISO)
negative regulation of innate immune response  (ISO)
negative regulation of interleukin-1-mediated signaling pathway  (ISO)
negative regulation of interleukin-12 production  (ISO)
negative regulation of interleukin-21 production  (ISO)
negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator  (ISO)
negative regulation of mitotic cell cycle  (ISO)
negative regulation of myofibroblast cell apoptotic process  (IMP)
negative regulation of neuron apoptotic process  (IDA,IMP)
negative regulation of NF-kappaB transcription factor activity  (ISO)
negative regulation of NIK/NF-kappaB signaling  (ISO)
negative regulation of regulatory T cell differentiation  (ISO)
negative regulation of stress fiber assembly  (ISO)
negative regulation of superoxide dismutase activity  (ISO)
negative regulation of transcription from RNA polymerase II promoter in response to oxidative stress  (IDA)
negative regulation of type I interferon production  (ISO)
negative regulation of type I interferon-mediated signaling pathway  (ISO)
negative regulation of vascular associated smooth muscle cell apoptotic process  (ISO)
negative regulation of vascular associated smooth muscle cell migration  (ISO)
phenotypic switching  (ISO)
positive regulation of activated T cell proliferation  (ISO)
positive regulation of angiogenesis  (ISO)
positive regulation of apoptotic process  (ISO)
positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis  (ISO)
positive regulation of cell growth  (ISO)
positive regulation of cell migration  (ISO)
positive regulation of cell population proliferation  (ISO)
positive regulation of collagen biosynthetic process  (IDA)
positive regulation of cytokine production  (ISO)
positive regulation of endothelial cell apoptotic process  (IMP)
positive regulation of endothelial cell differentiation  (ISO)
positive regulation of endothelial cell migration  (ISO)
positive regulation of endothelial tube morphogenesis  (IMP)
positive regulation of epithelial to mesenchymal transition  (ISO)
positive regulation of ERK1 and ERK2 cascade  (ISO)
positive regulation of fat cell differentiation  (ISO)
positive regulation of gene expression  (ISO)
positive regulation of inflammatory response  (ISO)
positive regulation of keratinocyte proliferation  (ISO)
positive regulation of leukocyte adhesion to vascular endothelial cell  (ISO)
positive regulation of metalloendopeptidase activity  (ISO)
positive regulation of myofibroblast differentiation  (IMP,ISO)
positive regulation of NLRP3 inflammasome complex assembly  (IDA)
positive regulation of osteoblast differentiation  (ISO)
positive regulation of phosphatidylinositol 3-kinase signaling  (IMP,ISO)
positive regulation of potassium ion export across plasma membrane  (ISO)
positive regulation of protein kinase B signaling  (ISO)
positive regulation of protein phosphorylation  (ISO)
positive regulation of replicative senescence  (ISO)
positive regulation of transforming growth factor beta receptor signaling pathway  (ISO)
positive regulation of type II interferon production  (ISO)
positive regulation of vascular associated smooth muscle cell differentiation  (ISO)
positive regulation of vascular associated smooth muscle cell migration  (ISO)
positive regulation of vascular associated smooth muscle cell proliferation  (ISO)
positive regulation of vascular associated smooth muscle contraction  (ISO)
positive regulation of vascular endothelial cell proliferation  (ISO)
positive regulation of vascular endothelial growth factor signaling pathway  (ISO)
positive regulation of wound healing  (IMP)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel  (ISO)
regulation of cell migration  (ISO)
regulation of cell shape  (ISO)
regulation of epidermal growth factor receptor signaling pathway  (ISO)
regulation of gene expression  (ISO)
regulation of mesenchymal stem cell differentiation  (IMP)
response to bacterium  (ISO)
response to hypoxia  (IEP)
response to muscle activity  (ISO)
response to oxygen levels  (ISO)

Cellular Component

Molecular Function


References - curated
# Reference Title Reference Citation
1. Two-stage genome-wide methylation profiling in childhood-onset Crohn's Disease implicates epigenetic alterations at the VMP1/MIR21 and HLA loci. Adams AT, etal., Inflamm Bowel Dis. 2014 Oct;20(10):1784-93. doi: 10.1097/MIB.0000000000000179.
2. Anti-inflammatory effects of miR-21 in the macrophage response to peritonitis. Barnett RE, etal., J Leukoc Biol. 2016 Feb;99(2):361-71. doi: 10.1189/jlb.4A1014-489R. Epub 2015 Sep 17.
3. MicroRNA-21 protects neurons from ischemic death. Buller B, etal., FEBS J. 2010 Oct;277(20):4299-307. doi: 10.1111/j.1742-4658.2010.07818.x. Epub 2010 Sep 14.
4. Up-Regulation of miR-21 Is Associated with Cervicitis and Human Papillomavirus Infection in Cervical Tissues. Bumrungthai S, etal., PLoS One. 2015 May 26;10(5):e0127109. doi: 10.1371/journal.pone.0127109. eCollection 2015.
5. Dual Role of MiR-21-Mediated Signaling in HUVECs and Rat Surgical Flap under Normoxia and Hypoxia Condition. Chang CH, etal., Int J Mol Sci. 2017 Sep 7;18(9). pii: ijms18091917. doi: 10.3390/ijms18091917.
6. MiR-320a contributes to atherogenesis by augmenting multiple risk factors and down-regulating SRF. Chen C, etal., J Cell Mol Med. 2015 May;19(5):970-85. doi: 10.1111/jcmm.12483. Epub 2015 Feb 27.
7. Overexpression of IL-9 induced by STAT3 phosphorylation is mediated by miR-155 and miR-21 in chronic lymphocytic leukemia. Chen N, etal., Oncol Rep. 2018 Jun;39(6):3064-3072. doi: 10.3892/or.2018.6367. Epub 2018 Apr 12.
8. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. Cheng Y, etal., J Mol Cell Cardiol. 2009 Jul;47(1):5-14. doi: 10.1016/j.yjmcc.2009.01.008. Epub 2009 Jan 27.
9. MicroRNA-21 regulates peroxisome proliferator-activated receptor alpha, a molecular mechanism of cardiac pathology in Cardiorenal Syndrome Type 4. Chuppa S, etal., Kidney Int. 2018 Feb;93(2):375-389. doi: 10.1016/j.kint.2017.05.014. Epub 2017 Jul 29.
10. Activation of the oncogenic miR-21-5p promotes HCV replication and steatosis induced by the viral core 3a protein. Clément S, etal., Liver Int. 2019 Jul;39(7):1226-1236. doi: 10.1111/liv.14112. Epub 2019 Apr 16.
11. Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. Correa-Gallego C, etal., PLoS One. 2016 Sep 29;11(9):e0163699. doi: 10.1371/journal.pone.0163699. eCollection 2016.
12. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Frezzetti D, etal., Oncogene. 2011 Jan 20;30(3):275-86. doi: 10.1038/onc.2010.416. Epub 2010 Oct 18.
13. miR-21 Expression Determines the Early Vaccine Immunity Induced by LdCen-/- Immunization. Gannavaram S, etal., Front Immunol. 2019 Sep 24;10:2273. doi: 10.3389/fimmu.2019.02273. eCollection 2019.
14. MicroRNA-21 contributes to high glucose-induced fibrosis in peritoneal mesothelial cells in rat models by activation of the Ras-MAPK signaling pathway via Sprouty-1. Gao Q, etal., J Cell Physiol. 2019 May;234(5):5915-5925. doi: 10.1002/jcp.26941. Epub 2018 Dec 4.
15. CCL20 Displays Antimicrobial Activity Against Cryptosporidium parvum, but Its Expression Is Reduced During Infection in the Intestine of Neonatal Mice. Guesdon W, etal., J Infect Dis. 2015 Oct 15;212(8):1332-40. doi: 10.1093/infdis/jiv206. Epub 2015 Apr 2.
16. MiR-21 confers resistance against CVB3-induced myocarditis by inhibiting PDCD4-mediated apoptosis. He J, etal., Clin Invest Med. 2013 Apr 1;36(2):E103-11. doi: 10.25011/cim.v36i2.19573.
17. Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways. Huang Q, etal., Int Immunopharmacol. 2019 Jan;66:41-51. doi: 10.1016/j.intimp.2018.11.006. Epub 2018 Nov 9.
18. Prognostic Significance of MicroRNA-21 Expression in Patients with Unresectable Metastatic Colon Cancer. Iseki Y, etal., Anticancer Res. 2016 Oct;36(10):5145-5151. doi: 10.21873/anticanres.11084.
19. MicroRNA-21 Is Required for Local and Remote Ischemic Preconditioning in Multiple Organ Protection Against Sepsis. Jia P, etal., Crit Care Med. 2017 Jul;45(7):e703-e710. doi: 10.1097/CCM.0000000000002363.
20. Serum miR-21 and miR-26a Levels Negatively Correlate with Severity of Cirrhosis in Patients with Chronic Hepatitis B. Jiang S, etal., Microrna. 2019;8(1):86-92. doi: 10.2174/2211536607666180821162850.
21. Expression and clinicopathological significance of microRNA-21 and programmed cell death 4 in malignant melanoma. Jiao J, etal., J Int Med Res. 2015 Oct;43(5):672-8. doi: 10.1177/0300060515583707. Epub 2015 Jul 6.
22. MicroRNA-21 Limits Uptake of Listeria monocytogenes by Macrophages to Reduce the Intracellular Niche and Control Infection. Johnston DGW, etal., Front Cell Infect Microbiol. 2017 May 23;7:201. doi: 10.3389/fcimb.2017.00201. eCollection 2017.
23. Correlation of the Levels of microRNA with Cell Composition of Axillary Lymph Node in Wistar Rats with Breast Cancer. Kabakov AV, etal., Bull Exp Biol Med. 2020 Feb;168(4):500-502. doi: 10.1007/s10517-020-04740-w. Epub 2020 Mar 10.
24. Systemic delivery of microRNA-21 antisense oligonucleotides to the brain using T7-peptide decorated exosomes. Kim G, etal., J Control Release. 2020 Jan 10;317:273-281. doi: 10.1016/j.jconrel.2019.11.009. Epub 2019 Nov 12.
25. Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer. Kim K, etal., Biochem Biophys Res Commun. 2020 Aug 27;529(3):707-713. doi: 10.1016/j.bbrc.2020.05.215. Epub 2020 Jul 18.
26. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2. Kim RY, etal., J Allergy Clin Immunol. 2017 Feb;139(2):519-532. doi: 10.1016/j.jaci.2016.04.038. Epub 2016 Jun 10.
27. Associations Between miRNAs and Two Different Cancers: Breast and Colon. Kundaktepe BP, etal., Cancer Manag Res. 2020 Feb 7;12:871-879. doi: 10.2147/CMAR.S227628. eCollection 2020.
28. MicroRNA-21 in cancer-associated fibroblasts supports lung adenocarcinoma progression. Kunita A, etal., Sci Rep. 2018 Jun 11;8(1):8838. doi: 10.1038/s41598-018-27128-3.
29. MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Li CX, etal., Nat Mater. 2017 Mar;16(3):379-389. doi: 10.1038/nmat4780. Epub 2016 Oct 31.
30. Circulating MicroRNA-21, MicroRNA-23a, and MicroRNA-125b as Biomarkers for Diagnosis and Prognosis of Burkitt Lymphoma in Children. Li J, etal., Med Sci Monit. 2016 Dec 19;22:4992-5002. doi: 10.12659/msm.897417.
31. MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway. Li W, etal., Inflammation. 2018 Mar;41(2):689-699. doi: 10.1007/s10753-017-0723-1.
32. LncRNA RUNX1-IT1 is Downregulated in Endometrial Cancer and Binds to miR-21 Precursor to Suppress Its Maturation. Liang M, etal., Cancer Manag Res. 2020 Dec 30;12:13451-13459. doi: 10.2147/CMAR.S272165. eCollection 2020.
33. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. Liu C, etal., J Hepatol. 2010 Jul;53(1):98-107. doi: 10.1016/j.jhep.2010.02.021. Epub 2010 Apr 4.
34. Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. Liu Q, etal., J BUON. 2018 Jan-Feb;23(1):29-35.
35. Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study. Liu W, etal., Pediatr Surg Int. 2016 Nov;32(11):1059-1065. doi: 10.1007/s00383-016-3960-8. Epub 2016 Sep 6.
36. MicroRNA-21 and -146b are involved in the pathogenesis of murine viral myocarditis by regulating TH-17 differentiation. Liu YL, etal., Arch Virol. 2013 Sep;158(9):1953-63. doi: 10.1007/s00705-013-1695-6. Epub 2013 Apr 16.
37. MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Liu ZL, etal., Mol Cell Biochem. 2013 Jan;372(1-2):35-45. doi: 10.1007/s11010-012-1443-3. Epub 2012 Sep 6.
38. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARα expression. Loyer X, etal., Gut. 2016 Nov;65(11):1882-1894. doi: 10.1136/gutjnl-2014-308883. Epub 2015 Sep 3.
39. Repression of microRNA-21 inhibits retinal vascular endothelial cell growth and angiogenesis via PTEN dependent-PI3K/Akt/VEGF signaling pathway in diabetic retinopathy. Lu JM, etal., Exp Eye Res. 2020 Jan;190:107886. doi: 10.1016/j.exer.2019.107886. Epub 2019 Nov 21.
40. MicroRNA-21-Regulated Activation of the Akt Pathway Participates in the Protective Effects of H2S against Liver Ischemia-Reperfusion Injury. Lu M, etal., Biol Pharm Bull. 2018 Feb 1;41(2):229-238. doi: 10.1248/bpb.b17-00769. Epub 2017 Nov 30.
41. Berberine regulates the microRNA-21-ITGΒ4-PDCD4 axis and inhibits colon cancer viability. Lü Y, etal., Oncol Lett. 2018 Apr;15(4):5971-5976. doi: 10.3892/ol.2018.7997. Epub 2018 Feb 8.
42. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Ma X, etal., Proc Natl Acad Sci U S A. 2011 Jun 21;108(25):10144-9. doi: 10.1073/pnas.1103735108. Epub 2011 Jun 6.
43. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Marquez RT, etal., Lab Invest. 2010 Dec;90(12):1727-36. doi: 10.1038/labinvest.2010.126. Epub 2010 Jul 12.
44. MicroRNA MIR21 and T Cells in Colorectal Cancer. Mima K, etal., Cancer Immunol Res. 2016 Jan;4(1):33-40. doi: 10.1158/2326-6066.CIR-15-0084. Epub 2015 Sep 29.
45. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival. Mima K, etal., Clin Cancer Res. 2016 Aug 1;22(15):3841-8. doi: 10.1158/1078-0432.CCR-15-2173. Epub 2016 Mar 8.
46. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Okayama H, etal., Int J Cancer. 2013 Jan 1;132(1):9-18. doi: 10.1002/ijc.27644. Epub 2012 Jun 13.
47. Dysregulated Serum MiRNA Profile and Promising Biomarkers in Dengue-infected Patients. Ouyang X, etal., Int J Med Sci. 2016 Feb 18;13(3):195-205. doi: 10.7150/ijms.13996. eCollection 2016.
48. Induction of specific microRNAs inhibits cutaneous wound healing. Pastar I, etal., J Biol Chem. 2012 Aug 24;287(35):29324-35. doi: 10.1074/jbc.M112.382135. Epub 2012 Jul 6.
49. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Ren XP, etal., Circulation. 2009 May 5;119(17):2357-2366. doi: 10.1161/CIRCULATIONAHA.108.814145. Epub 2009 Apr 20.
50. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
51. Neurotrophin-3 mRNA a putative target of miR21 following status epilepticus. Risbud RM, etal., Brain Res. 2011 Nov 18;1424:53-9. doi: 10.1016/j.brainres.2011.09.039. Epub 2011 Sep 24.
52. Protein Deimination Signatures in Plasma and Plasma-EVs and Protein Deimination in the Brain Vasculature in a Rat Model of Pre-Motor Parkinson's Disease. Sancandi M, etal., Int J Mol Sci. 2020 Apr 15;21(8). pii: ijms21082743. doi: 10.3390/ijms21082743.
53. miR-21 enhances the protective effect of loperamide on rat cardiomyocytes against hypoxia/reoxygenation, reactive oxygen species production and apoptosis via regulating Akap8 and Bard1 expression. Shen H, etal., Exp Ther Med. 2019 Feb;17(2):1312-1320. doi: 10.3892/etm.2018.7047. Epub 2018 Dec 5.
54. MicroRNA-21 knockout improve the survival rate in DSS induced fatal colitis through protecting against inflammation and tissue injury. Shi C, etal., PLoS One. 2013 Jun 24;8(6):e66814. doi: 10.1371/journal.pone.0066814. Print 2013.
55. Adenovirus-mediated down-regulation of miR-21-5p alleviates experimental autoimmune uveoretinitis in mice. Shi L, etal., Int Immunopharmacol. 2019 Sep;74:105698. doi: 10.1016/j.intimp.2019.105698. Epub 2019 Jun 19.
56. [Effects of microRNA-21 inhibitor on apoptosis of type II alveolar epithelial cells in rats with hyperoxia-induced acute lung injury]. Shi L, etal., Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2017 Mar;29(3):244-248. doi: 10.3760/cma.j.issn.2095-4352.2017.03.010.
57. Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group. Silakit R, etal., Parasitol Int. 2017 Aug;66(4):479-485. doi: 10.1016/j.parint.2015.10.001. Epub 2015 Oct 9.
58. Integrating DNA methylation and microRNA biomarkers in sputum for lung cancer detection. Su Y, etal., Clin Epigenetics. 2016 Oct 19;8:109. doi: 10.1186/s13148-016-0275-5. eCollection 2016.
59. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer. Sun M, etal., Dis Markers. 2016;2016:3823121. doi: 10.1155/2016/3823121. Epub 2016 Jan 11.
60. Mir-21 Mediates the Inhibitory Effect of Ang (1-7) on AngII-induced NLRP3 Inflammasome Activation by Targeting Spry1 in lung fibroblasts. Sun NN, etal., Sci Rep. 2017 Oct 30;7(1):14369. doi: 10.1038/s41598-017-13305-3.
61. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Takeuchi-Yorimoto A, etal., Toxicol Lett. 2016 Sep 6;258:159-167. doi: 10.1016/j.toxlet.2016.06.012. Epub 2016 Jun 15.
62. Targeting of microRNA-21-5p protects against seizure damage in a kainic acid-induced status epilepticus model via PTEN-mTOR. Tang C, etal., Epilepsy Res. 2018 Aug;144:34-42. doi: 10.1016/j.eplepsyres.2018.05.001. Epub 2018 May 4.
63. MicroRNA-21 promotes cell metastasis in cervical cancer through modulating epithelial-mesenchymal transition. Tang Y, etal., Oncol Lett. 2020 Apr;19(4):3289-3295. doi: 10.3892/ol.2020.11438. Epub 2020 Mar 3.
64. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Thum T, etal., Nature. 2008 Dec 18;456(7224):980-4. doi: 10.1038/nature07511. Epub 2008 Nov 30.
65. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Toldo S, etal., Circ Cardiovasc Genet. 2014 Jun;7(3):311-20. doi: 10.1161/CIRCGENETICS.113.000381. Epub 2014 May 13.
66. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. Tomimaru Y, etal., J Hepatol. 2012 Jan;56(1):167-75. doi: 10.1016/j.jhep.2011.04.026. Epub 2011 Jul 13.
67. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. Wang B and Zhang Q, J Cancer Res Clin Oncol. 2012 Oct;138(10):1659-66. doi: 10.1007/s00432-012-1244-9. Epub 2012 May 26.
68. Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Wang H, etal., Biomed Res Int. 2014;2014:864894. doi: 10.1155/2014/864894. Epub 2014 May 18.
69. MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. Wang X, etal., PLoS One. 2017 Sep 8;12(9):e0184292. doi: 10.1371/journal.pone.0184292. eCollection 2017.
70. Ski-related novel protein suppresses the development of diabetic nephropathy by modulating transforming growth factor-β signaling and microRNA-21 expression. Wang Y, etal., J Cell Physiol. 2019 Aug;234(10):17925-17936. doi: 10.1002/jcp.28425. Epub 2019 Mar 7.
71. The association between microRNA-21 and hypertension-induced cardiac remodeling. Watanabe K, etal., PLoS One. 2020 Feb 10;15(2):e0226053. doi: 10.1371/journal.pone.0226053. eCollection 2020.
72. Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Winther M, etal., Acta Oncol. 2015;54(9):1582-91. doi: 10.3109/0284186X.2015.1064161.
73. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer. Wu YR, etal., Tumour Biol. 2016 Sep;37(9):12061-12070. doi: 10.1007/s13277-016-5074-2. Epub 2016 May 17.
74. miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock. Xue Z, etal., Cell Death Dis. 2019 Jun 12;10(6):461. doi: 10.1038/s41419-019-1713-z.
75. MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3). Yang CH, etal., J Biol Chem. 2014 Sep 5;289(36):25079-87. doi: 10.1074/jbc.M114.593863. Epub 2014 Jul 24.
76. Effect of Corilagin on the miR-21/smad7/ERK signaling pathway in a schistosomiasis-induced hepatic fibrosis mouse model. Yang F, etal., Parasitol Int. 2016 Aug;65(4):308-15. doi: 10.1016/j.parint.2016.03.001. Epub 2016 Mar 2.
77. Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4. Yang Y, etal., Cancer Gene Ther. 2015 Jan;22(1):23-9. doi: 10.1038/cgt.2014.66. Epub 2014 Dec 5.
78. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. Yang Y, etal., Gastroenterology. 2017 Mar;152(4):851-866.e24. doi: 10.1053/j.gastro.2016.11.018. Epub 2016 Nov 19.
79. Osthole attenuates pulmonary arterial hypertension by the regulation of sphingosine 1-phosphate in rats. Yao L, etal., Chin J Nat Med. 2020 Apr;18(4):308-320. doi: 10.1016/S1875-5364(20)30038-8.
80. CircRNA circ_0026344 as a prognostic biomarker suppresses colorectal cancer progression via microRNA-21 and microRNA-31. Yuan Y, etal., Biochem Biophys Res Commun. 2018 Sep 5;503(2):870-875. doi: 10.1016/j.bbrc.2018.06.089. Epub 2018 Jun 23.
81. Circular RNA circ_0001287 inhibits the proliferation, metastasis, and radiosensitivity of non-small cell lung cancer cells by sponging microRNA miR-21 and up-regulating phosphatase and tensin homolog expression. Zhang CC, etal., Bioengineered. 2021 Dec;12(1):414-425. doi: 10.1080/21655979.2021.1872191.
82. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Zhang JG, etal., Clin Chim Acta. 2010 Jun 3;411(11-12):846-52. doi: 10.1016/j.cca.2010.02.074. Epub 2010 Mar 16.
83. Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats. Zhang K, etal., Cardiovasc Ther. 2018 Dec;36(6):e12466. doi: 10.1111/1755-5922.12466. Epub 2018 Sep 29.
84. MicroRNA-21 is upregulated during intestinal barrier dysfunction induced by ischemia reperfusion. Zhang L, etal., Kaohsiung J Med Sci. 2018 Oct;34(10):556-563. doi: 10.1016/j.kjms.2018.05.006. Epub 2018 Jun 7.
85. [Effect of overexpression of microRNA-21-5p on early apoptosis of type II alveolar epithelial cells in rats with hyperoxic acute lung injury]. Zhang W, etal., Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019 Aug;31(8):978-982. doi: 10.3760/cma.j.issn.2095-4352.2019.08.013.
86. [Clinicopathological significance of microRNA-21 and miR-125 expression in colorectal cancer]. Zhang Y, etal., Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Nov;12(6):623-6.
87. MiR-21 and miR-222 inhibit apoptosis of adult dorsal root ganglion neurons by repressing TIMP3 following sciatic nerve injury. Zhou S, etal., Neurosci Lett. 2015 Jan 23;586:43-9. doi: 10.1016/j.neulet.2014.12.006. Epub 2014 Dec 4.
88. Mesenchymal stem cell derived EVs mediate neuroprotection after spinal cord injury in rats via the microRNA-21-5p/FasL gene axis. Zhou X, etal., Biomed Pharmacother. 2019 Jul;115:108818. doi: 10.1016/j.biopha.2019.108818. Epub 2019 May 16.
89. Inflammation-Related MicroRNAs Are Associated with Plaque Stability Calculated by IVUS in Coronary Heart Disease Patients. Zhu GF, etal., J Interv Cardiol. 2019 Dec 1;2019:9723129. doi: 10.1155/2019/9723129. eCollection 2019.
90. Role of HIF-1α in Cold Ischemia Injury of Rat Donor Heart Via the miR-21/PDCD4 Pathway. Zhu L, etal., Transplant Proc. 2020 Jan - Feb;52(1):383-391. doi: 10.1016/j.transproceed.2019.11.001. Epub 2020 Jan 17.
91. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Zhu S, etal., Cell Res. 2008 Mar;18(3):350-9. doi: 10.1038/cr.2008.24.
92. MicroRNA-21 inhibits lipopolysaccharide-induced acute lung injury by targeting nuclear factor-κB. Zhu WD, etal., Exp Ther Med. 2018 Dec;16(6):4616-4622. doi: 10.3892/etm.2018.6789. Epub 2018 Sep 24.
Additional References at PubMed
PMID:14691248   PMID:16381832   PMID:16766679   PMID:17604727   PMID:17805466   PMID:18556655   PMID:18723672   PMID:18850008   PMID:19147652   PMID:20086200   PMID:20219857   PMID:20403161  
PMID:20439489   PMID:20498256   PMID:21162128   PMID:21698002   PMID:21704009   PMID:21852586   PMID:21853131   PMID:22022489   PMID:22503104   PMID:22517757   PMID:22790595   PMID:22907769  
PMID:23097335   PMID:23154340   PMID:23185045   PMID:23473787   PMID:23647386   PMID:23665014   PMID:23902531   PMID:23978520   PMID:24161401   PMID:24205035   PMID:24237305   PMID:24388835  
PMID:24391219   PMID:24492999   PMID:24556821   PMID:24562307   PMID:24676391   PMID:24743145   PMID:24903275   PMID:24913635   PMID:24951588   PMID:25106556   PMID:25108037   PMID:25156787  
PMID:25483877   PMID:25504627   PMID:25536091   PMID:25598202   PMID:25633833   PMID:25704671   PMID:25840830   PMID:25879024   PMID:25973032   PMID:26302266   PMID:26323253   PMID:26380976  
PMID:26415649   PMID:26621219   PMID:26830133   PMID:26862785   PMID:27053343   PMID:27075111   PMID:27152763   PMID:27226339   PMID:27336721   PMID:27429986   PMID:27634014   PMID:27680680  
PMID:27708252   PMID:27803763   PMID:27979484   PMID:27999792   PMID:28214900   PMID:28335740   PMID:28347692   PMID:28374893   PMID:28402262   PMID:28473352   PMID:28656242   PMID:28731181  
PMID:28807003   PMID:28939387   PMID:28971796   PMID:29028768   PMID:29115610   PMID:29248491   PMID:29355689   PMID:29436647   PMID:29444190   PMID:29461599   PMID:29627835   PMID:29696468  
PMID:29709341   PMID:29795410   PMID:29925839   PMID:29968904   PMID:30089893   PMID:30132829   PMID:30256395   PMID:30463111   PMID:30504734   PMID:30536340   PMID:30657727   PMID:30830529  
PMID:30861181   PMID:30871773   PMID:30915769   PMID:31002122   PMID:31115556   PMID:31161659   PMID:31210327   PMID:31223614   PMID:31362482   PMID:31389569   PMID:31389580   PMID:31389582  
PMID:31400088   PMID:31416448   PMID:31430983   PMID:31605737   PMID:31646590   PMID:31707083   PMID:31782491   PMID:31919615   PMID:31982471   PMID:32016994   PMID:32050796   PMID:32108985  
PMID:32306124   PMID:32308118   PMID:32377742   PMID:32507001   PMID:32789575   PMID:32791063   PMID:33021357   PMID:33026076   PMID:33151961   PMID:33385416   PMID:33391474   PMID:33494833  
PMID:33681349   PMID:33730297   PMID:33733575   PMID:33785732   PMID:34246804   PMID:34323223   PMID:34326064   PMID:34506261   PMID:34617873   PMID:34796728   PMID:34901270   PMID:34904852  
PMID:35132352   PMID:35159373   PMID:35279183   PMID:35617312   PMID:35985609   PMID:37098739  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.21071,405,257 - 71,405,348 (-)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl1071,405,257 - 71,405,348 (-)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx1076,026,707 - 76,026,798 (-)NCBIRnor_SHR
UTH_Rnor_SHRSP_BbbUtx_1.01075,531,582 - 75,531,673 (-)NCBIRnor_SHRSP
UTH_Rnor_WKY_Bbb_1.01070,996,132 - 70,996,223 (-)NCBIRnor_WKY
Rnor_6.01073,902,210 - 73,902,301 (-)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl1073,902,210 - 73,902,301 (-)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.01076,197,081 - 76,197,172 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
Celera1070,326,375 - 70,326,466 (-)NCBICelera
Cytogenetic Map10q26NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh381759,841,266 - 59,841,337 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p13 Ensembl1759,841,266 - 59,841,337 (+)EnsemblGRCh38hg38GRCh38
GRCh371757,918,627 - 57,918,698 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 361755,273,408 - 55,273,479 (+)NCBINCBI36Build 36hg18NCBI36
Celera1754,382,140 - 54,382,211 (+)NCBICelera
Cytogenetic Map17q23.1NCBI
HuRef1753,291,116 - 53,291,187 (+)NCBIHuRef
CHM1_11757,982,648 - 57,982,719 (+)NCBICHM1_1
T2T-CHM13v2.01760,710,020 - 60,710,091 (+)NCBIT2T-CHM13v2.0
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm391186,474,893 - 86,474,984 (-)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1186,474,893 - 86,474,984 (-)EnsemblGRCm39 Ensembl
GRCm381186,584,067 - 86,584,158 (-)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1186,584,067 - 86,584,158 (-)EnsemblGRCm38mm10GRCm38
MGSCv371186,397,569 - 86,397,660 (-)NCBIGRCm37MGSCv37mm9NCBIm37
Celera1196,199,974 - 96,200,065 (-)NCBICelera
Cytogenetic Map11CNCBI
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.1934,340,550 - 34,340,609 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl934,340,533 - 34,340,624 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha933,572,293 - 33,572,352 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.0935,150,885 - 35,150,944 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl935,150,868 - 35,150,959 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.1933,934,637 - 33,934,696 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.0934,220,122 - 34,220,181 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.0934,306,261 - 34,306,320 (+)NCBIUU_Cfam_GSD_1.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1236,065,267 - 36,065,358 (+)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11236,065,267 - 36,065,358 (+)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21237,340,385 - 37,340,476 (+)NCBISscrofa10.2Sscrofa10.2susScr3

miRNA Target Status

Confirmed Targets
Gene TargetMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Pdcd4rno-miR-21-5pMirtarbaseexternal_infoLuciferase reporter assay//Western blotFunctional MTI19158092
Pdcd4rno-miR-21-5pMirtarbaseexternal_infoWestern blot//qRT-PCR//GFP reporter assay//LuciferFunctional MTI19336275
Pdcd4rno-miR-21-5pMirtarbaseexternal_infoWestern blotFunctional MTI19167416
Pdcd4rno-miR-21-5pMirtarbaseexternal_infoqRT-PCR//Western blotFunctional MTI21154462
Pdcd4rno-miR-21-5pMirtarbaseexternal_infoImmunocytochemistry//Immunofluorescence//LuciferasFunctional MTI22565856
Tpm1rno-miR-21-5pMirtarbaseexternal_infoMicroarrayFunctional MTI (Weak)18258830
Ptenrno-miR-21-5pMirtarbaseexternal_infoMicroarray//qRT-PCR//Western blotFunctional MTI17478730
Faslgrno-miR-21-5pMirtarbaseexternal_infoImmunofluorescence//In situ hybridization//LuciferFunctional MTI20840605
Elavl4rno-miR-21-5pMirtarbaseexternal_infoqRT-PCRFunctional MTI (Weak)20584986

Predicted Targets
Summary Value
Count of predictions:6874
Count of gene targets:4588
Count of transcripts:4943
Interacting mature miRNAs:rno-miR-21-3p, rno-miR-21-5p
Prediction methods:Microtar, Miranda, Pita, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
70223Bp57Blood pressure QTL 575arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)10180676123Rat
8662860Vetf10Vascular elastic tissue fragility QTL 10artery integrity trait (VT:0010639)number of ruptures of the internal elastic lamina of the abdominal aorta and iliac arteries (CMO:0002562)10615418273453136Rat
61427Cia16Collagen induced arthritis QTL 163.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)10635789696121100Rat
2303118Mamtr7Mammary tumor resistance QTL 70.003mammary gland integrity trait (VT:0010552)mammary tumor growth rate (CMO:0000344)109658275104670812Rat
2301967Cm73Cardiac mass QTL 734.55heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)101448701189062041Rat
631268Cia21Collagen induced arthritis QTL 213.1joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1014487011104060283Rat
2316949Gluco60Glucose level QTL 603.7blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)1014487011107057807Rat
1554317Bmd4Bone mineral density QTL 49.40.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)101981604299406971Rat
724556Pur2Proteinuria QTL 25.5urine protein amount (VT:0005160)urine protein level (CMO:0000591)102242750090627625Rat
61354Pia10Pristane induced arthritis QTL 100.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
631267Cia20Collagen induced arthritis QTL 203.2joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
61325Aia5Adjuvant induced arthritis QTL 50.01joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1023444813104060283Rat
1298069Bp168Blood pressure QTL 1685.5blood pressure trait (VT:0000183)systolic blood pressure (CMO:0000004)102652195798003205Rat
631542Bp82Blood pressure QTL 826.8arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)102652195798952741Rat
2300171Bmd58Bone mineral density QTL 584.90.0001lumbar vertebra mineral mass (VT:0010511)volumetric bone mineral density (CMO:0001553)102694462871944628Rat
10402859Bp381Blood pressure QTL 3810.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102760646872606468Rat
2292441Bp308Blood pressure QTL 308arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102760646872606468Rat
724527Bp148Blood pressure QTL 1480.0001arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)102845313673453136Rat
1331791Cm31Cardiac mass QTL 313.84606heart mass (VT:0007028)heart wet weight (CMO:0000069)1029299504107211142Rat
631557Bp136Blood pressure QTL 1360.003arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)103063205375632053Rat
1576311Pia26Pristane induced arthritis QTL 26joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)103122402675632053Rat
1578779Tcas10Tongue tumor susceptibility QTL 103.12tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)103129743976297439Rat
1576319Cia29Collagen induced arthritis QTL 29joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)103397392178973921Rat
2317042Aia20Adjuvant induced arthritis QTL 203.38joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)103756507982565079Rat
2317043Aia7Adjuvant induced arthritis QTL 73.82joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)103756507982565079Rat
1576308Schws1Schwannoma susceptibility QTL 10.0041nervous system integrity trait (VT:0010566)percentage of study population developing trigeminal nerve neurilemmomas during a period of time (CMO:0002017)1040035094102359817Rat
631269Cia22Collagen induced arthritis QTL 228.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631270Cia23Collagen induced arthritis QTL 233.9joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)1040035094104060283Rat
631552Vetf2Vascular elastic tissue fragility QTL 24.50.0002aorta elastic tissue integrity trait (VT:0010556)artery internal elastic lamina non-tumorous lesion count (CMO:0001913)104114263386142633Rat
61463Bp12Blood pressure QTL 126.30.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104133325886333258Rat
8552805Bw145Body weight QTL 1452.2body mass (VT:0001259)change in body weight to body weight ratio (CMO:0002216)104194452678307017Rat
1298078Stresp5Stress response QTL 52.990.00025blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)1042045676104670812Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)14232313287323132Rat
70188BpQTLcluster1Blood pressure QTL cluster 14.864arterial blood pressure trait (VT:2000000)pulse pressure (CMO:0000292)14232313287323132Rat
70198BpQTLcluster9Blood pressure QTL cluster 92.94arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)104232313287323132Rat
6893342Cm78Cardiac mass QTL 780.10.88heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)104287676679813922Rat
9589030Epfw9Epididymal fat weight QTL 919.240.001epididymal fat pad mass (VT:0010421)epididymal fat pad weight to body weight ratio (CMO:0000658)104444169989441699Rat
7411614Foco18Food consumption QTL 180.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)104444169989441699Rat
8694173Bw149Body weight QTL 1494.380.001body mass (VT:0001259)body weight gain (CMO:0000420)104444169989441699Rat
2300218Hpcl2Hepatic cholesterol level QTL 2liver cholesterol amount (VT:0010498)liver cholesterol level (CMO:0001597)104502965095600334Rat
631547Bp87Blood pressure QTL 874.5arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)104736947092369470Rat
2293705Bmd25Bone mineral density QTL 257.10.0001femur mineral mass (VT:0010011)compact volumetric bone mineral density (CMO:0001730)104944455181709989Rat
7207811Bmd90Bone mineral density QTL 905.2femur size trait (VT:1000369)femoral neck cross-sectional area (CMO:0001697)104944455181709989Rat
2293652Bmd22Bone mineral density QTL 224.90.0001femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)104944455181709989Rat
2293669Bmd33Bone mineral density QTL 334.50.0001femur strength trait (VT:0010010)femoral neck polar moment of inertia (CMO:0001670)104944455181709989Rat
2293679Bmd30Bone mineral density QTL 303.50.0001femur mineral mass (VT:0010011)total volumetric bone mineral density (CMO:0001728)104944455181709989Rat
1549846Scl47Serum cholesterol level QTL 473.6blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)105057470795574707Rat
70364Bp72Blood pressure QTL 72arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)105112110096121100Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1051770177107211142Rat
61387Bp1Blood pressure QTL 15.1arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)1051770177107211142Rat
1359017Hrtrt21Heart rate QTL 212.4heart pumping trait (VT:2000009)heart rate (CMO:0000002)105177294096772940Rat
631530Tls3T-lymphoma susceptibility QTL 300.0001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)105177461295600334Rat
631535Cm51Cardiac mass QTL 513heart mass (VT:0007028)calculated heart weight (CMO:0000073)105178628291669536Rat
70171Cari1Carrageenan-induced inflammation QTL 14.90.0005hypodermis integrity trait (VT:0010550)inflammatory exudate volume (CMO:0001429)1053797385107211142Rat
70164Bw21Body weight QTL 214.360.00005body mass (VT:0001259)body weight (CMO:0000012)105379749498952626Rat
1354608Cm33Cardiac mass QTL 332.8heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)105480929299809292Rat
2312662Slep8Serum leptin concentration QTL 80.05blood leptin amount (VT:0005667)serum leptin level (CMO:0000780)1057134272102134272Rat
2312668Scl65Serum cholesterol level QTL 650.001blood cholesterol amount (VT:0000180)serum total cholesterol level (CMO:0000363)1057134272102134272Rat
2312672Insul15Insulin level QTL 150.01blood insulin amount (VT:0001560)serum insulin level (CMO:0000358)1057134272102134272Rat
1549831Bss6Bone structure and strength QTL 64lumbar vertebra strength trait (VT:0010574)vertebra ultimate force (CMO:0001678)1057576521102576521Rat
2293698Bss43Bone structure and strength QTL 435.330.0001lumbar vertebra size trait (VT:0010518)lumbar vertebra cross-sectional area (CMO:0001689)1059209888104209888Rat
70363Bp71Blood pressure QTL 710.04arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)106134527681714865Rat
2306970Anxrr22Anxiety related response QTL 225.95fear/anxiety-related behavior trait (VT:1000241)number of periods of voluntary immobility (CMO:0001045)106134527698211570Rat
6893336Cm75Cardiac mass QTL 750.10.87heart mass (VT:0007028)heart weight to body weight ratio (CMO:0000074)106134527699703528Rat
1558643Cm44Cardiac mass QTL 444.80.0000368heart mass (VT:0007028)heart wet weight (CMO:0000069)106134527699703528Rat
61402Niddm3Non-insulin dependent diabetes mellitus QTL 34.58blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)106134541382564856Rat
2313103Bss80Bone structure and strength QTL 8020.0001tibia strength trait (VT:1000284)tibia midshaft endosteal cross-sectional area (CMO:0001716)1062057807107057807Rat
2313105Bss79Bone structure and strength QTL 791.80.0001tibia size trait (VT:0100001)tibia midshaft cross-sectional area (CMO:0001717)1062057807107057807Rat
61449Ciaa2CIA Autoantibody QTL 27.1blood autoantibody amount (VT:0003725)calculated serum anti-type 2 collagen antibody titer (CMO:0001279)1063221094107211142Rat
2298481Eau9Experimental allergic uveoretinitis QTL 90.0169uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)106592723382565079Rat
1357344Bp249Blood pressure QTL 2490.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106674365598003205Rat
631565Hcuc4Hepatic copper content QTL 44.15liver copper amount (VT:0003065)liver copper weight to liver dry weight ratio (CMO:0001512)106694181373452992Rat
2317029Aia19Adjuvant induced arthritis QTL 192.98joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)1066978955107211142Rat
2317039Aia6Adjuvant induced arthritis QTL 64.31joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)1066978955107211142Rat
2289985Bp305Blood pressure QTL 305arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)106750210873579767Rat
10450498Bp384Blood pressure QTL 3840.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)1067750049107211142Rat
1642980Bp300Blood pressure QTL 300arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068383129107211142Rat
61396Bp9Blood pressure QTL 94.80.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)1068420376107211142Rat
2300172Bmd57Bone mineral density QTL 579.80.0001femur mineral mass (VT:0010011)volumetric bone mineral density (CMO:0001553)1069738412107211142Rat
2293646Bss25Bone structure and strength QTL 2510.960.0001femur morphology trait (VT:0000559)femur cross-sectional area (CMO:0001661)1069738412107211142Rat
2293663Bss33Bone structure and strength QTL 339.340.0001femur strength trait (VT:0010010)femur midshaft polar moment of inertia (CMO:0001669)1069738412107211142Rat
6893366Bw106Body weight QTL 1060.30.47body mass (VT:0001259)body weight (CMO:0000012)1070199100107211142Rat
10450500Bp385Blood pressure QTL 3850.002arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107111521771966743Rat
2292439Bp309Blood pressure QTL 309arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107111521771966743Rat
12903245Cm110Cardiac mass QTL 1100.001heart mass (VT:0007028)heart wet weight to body weight ratio (CMO:0002408)107111521772606468Rat
12903246Cm111Cardiac mass QTL 1110.001heart left ventricle mass (VT:0007031)heart left ventricle weight to body weight ratio (CMO:0000530)107111521772606468Rat
12903247Cm112Cardiac mass QTL 1120.001heart right ventricle mass (VT:0007033)heart right ventricle weight to body weight ratio (CMO:0000914)107111521772606468Rat
12903248Am14Aortic mass QTL 140.001aorta mass (VT:0002845)aorta weight to aorta length to body weight ratio (CMO:0002722)107111521772606468Rat
12903249Kidm68Kidney mass QTL 680.02kidney mass (VT:0002707)both kidneys wet weight to body weight ratio (CMO:0000340)107111521772606468Rat
12902615Bw185Body weight QTL 1850.01body mass (VT:0001259)body weight (CMO:0000012)107111521772606468Rat
1579918Bp279Blood pressure QTL 2790.01arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)107111521772606468Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21071,406,200 - 71,406,306 (+)MAPPERmRatBN7.2
mRatBN7.21195,875,222 - 195,875,328 (+)MAPPERmRatBN7.2
Rnor_6.01213,546,690 - 213,546,795NCBIRnor6.0
Rnor_6.01073,903,154 - 73,903,259NCBIRnor6.0
Rnor_5.01076,196,123 - 76,196,228UniSTSRnor5.0
Rnor_5.01220,441,627 - 220,441,732UniSTSRnor5.0
RGSC_v3.41200,953,414 - 200,953,519UniSTSRGSC3.4
RGSC_v3.41074,865,444 - 74,865,549UniSTSRGSC3.4
Celera1070,327,319 - 70,327,424UniSTS
Celera1193,519,273 - 193,519,378UniSTS
Cytogenetic Map1q41UniSTS
Cytogenetic Map10q26UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.22182,788,905 - 182,789,088 (+)MAPPERmRatBN7.2
mRatBN7.21071,405,085 - 71,405,261 (+)MAPPERmRatBN7.2
mRatBN7.21071,405,078 - 71,405,261 (+)MAPPERmRatBN7.2
mRatBN7.22182,788,912 - 182,789,088 (+)MAPPERmRatBN7.2
Rnor_6.02196,386,053 - 196,386,235NCBIRnor6.0
Rnor_6.01073,902,032 - 73,902,214NCBIRnor6.0
Rnor_5.01076,197,168 - 76,197,350UniSTSRnor5.0
Rnor_5.02215,882,523 - 215,882,705UniSTSRnor5.0
RGSC_v3.42190,121,004 - 190,121,186UniSTSRGSC3.4
RGSC_v3.41074,864,322 - 74,864,504UniSTSRGSC3.4
Celera1070,326,197 - 70,326,379UniSTS
Celera2175,322,649 - 175,322,831UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21195,875,497 - 195,875,652 (+)MAPPERmRatBN7.2
mRatBN7.21071,405,948 - 71,406,103 (+)MAPPERmRatBN7.2
Rnor_6.01073,902,902 - 73,903,056NCBIRnor6.0
Rnor_6.01213,546,965 - 213,547,119NCBIRnor6.0
Rnor_5.01076,196,326 - 76,196,480UniSTSRnor5.0
Rnor_5.01220,441,902 - 220,442,056UniSTSRnor5.0
RGSC_v3.41200,953,689 - 200,953,843UniSTSRGSC3.4
RGSC_v3.41074,865,192 - 74,865,346UniSTSRGSC3.4
Celera1070,327,067 - 70,327,221UniSTS
Celera1193,519,550 - 193,519,704UniSTS
Cytogenetic Map10q26UniSTS
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.21071,405,555 - 71,405,714 (+)MAPPERmRatBN7.2
Rnor_6.01073,902,509 - 73,902,667NCBIRnor6.0
Rnor_5.01076,196,715 - 76,196,873UniSTSRnor5.0
RGSC_v3.41074,864,799 - 74,864,957UniSTSRGSC3.4
Celera1070,326,674 - 70,326,832UniSTS
Cytogenetic Map10q26UniSTS


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 2 2 7 3 2
Low 3 26 35 21 16 21 7 9 57 25 30 9 7
Below cutoff 9 2 2 1 2 2 1


Reference Sequences
RefSeq Acc Id: ENSRNOT00000053603
RefSeq Status:
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl1071,405,257 - 71,405,348 (-)Ensembl
Rnor_6.0 Ensembl1073,902,210 - 73,902,301 (-)Ensembl
RefSeq Acc Id: NR_031823
Rat AssemblyChrPosition (strand)Source
mRatBN7.21071,405,257 - 71,405,348 (-)NCBI
Rnor_6.01073,902,210 - 73,902,301 (-)NCBI
Rnor_5.01076,197,081 - 76,197,172 (+)NCBI
Celera1070,326,375 - 70,326,466 (-)NCBI

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:2325598 AgrOrtholog
BioCyc Gene G2FUF-23796 BioCyc
Ensembl Genes ENSRNOG00000035480 Ensembl, ENTREZGENE
Ensembl Transcript ENSRNOT00000053603 ENTREZGENE
miRBase MI0000850 ENTREZGENE
NCBI Gene 100314000 ENTREZGENE
PhenoGen Mir21 PhenoGen
RNAcentral URS0000013967 RNACentral
  URS000015930E RNACentral
  URS000039ED8D RNACentral

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2013-08-14 Mir21  microRNA 21  Mir21  microRNA mir-21  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2010-06-02 Mir21  microRNA mir-21      Symbol and Name status set to provisional 70820 PROVISIONAL